Oxford Nanopore Technologies
Oxford Nanopore Technologies
ONT
LSE
1.17
GBX
-98.74%
About
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing.
Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing.
GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 725.9K |
| Three Month Average Volume | 36.5M |
| High Low | |
| Fifty-Two Week High | 2.434 GBX |
| Fifty-Two Week Low | 0.85 GBX |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 27 Jun 2024 |
| Price and Volume | |
| Current Price | 1.173 GBX |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.12% |
| Thirteen Week Relative Price Change | 7.89% |
| Twenty-Six Week Relative Price Change | -17.25% |
| Fifty-Two Week Relative Price Change | -56.28% |
| Year-to-Date Relative Price Change | -47.90% |
| Price Change | |
| One Day Price Change | -1.01% |
| Thirteen Week Price Change | 9.32% |
| Twenty-Six Week Price Change | -9.77% |
| Five Day Price Change | -3.69% |
| Fifty-Two Week Price Change | -50.71% |
| Year-to-Date Price Change | -43.66% |
| Month-to-Date Price Change | -2.90% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.74934 GBX |
| Book Value Per Share (Most Recent Quarter) | 0.74934 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.71104 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.71104 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.15226 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.20345 GBX |
| Revenue Per Share (Trailing Twelve Months) | 0.20345 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend Per Share (5 Year) | -99999.99 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.18527 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.18514 GBX |
| Normalized (Last Fiscal Year) | -0.18253 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.18527 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.18514 GBX |
| Including Extraordinary Items (Last Fiscal Year) | -0.18527 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | -0.18514 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.3143 GBX |
| Cash Per Share (Most Recent Quarter) | 0.3143 GBX |
| Cash Flow Per Share (Last Fiscal Year) | -0.13535 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | -0.13535 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.19736 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -76 |
| Cash Flow Revenue (Trailing Twelve Months) | -97 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -88.27% |
| Pretax Margin (Last Fiscal Year) | -88.27% |
| Pretax Margin (5 Year) | -82.78% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 53.33% |
| Gross Margin (Trailing Twelve Months) | 53.33% |
| Gross Margin (5 Year) | 53.90% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99.29% |
| Operating Margin (Trailing Twelve Months) | -99.29% |
| Operating Margin (5 Year) | -88.17% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -91.06% |
| Net Profit Margin (Trailing Twelve Months) | -91.06% |
| Net Profit Margin (5 Year) | -81.85% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 33.04% |
| Tangible Book Value (5 Year) | 34.95% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 9.72% |
| Revenue Growth (3 Year) | 39.15% |
| Revenue Change (Trailing Twelve Months) | -14.57% |
| Revenue Per Share Growth | 38.45% |
| Revenue Growth (5 Year) | 14.22% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 8.92% |
| Total Debt (5 Year) | 34.40% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -36.01% |
| EPS Change (Trailing Twelve Months) | -67.61% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -228,395,000 |
| Net Debt (Last Fiscal Year) | -228,395,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 7 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 6 |
| Long Term Debt to Equity (Most Recent Quarter) | 6 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 4 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -164,592,000 |
| Free Cash Flow (Trailing Twelve Months) | -164,592,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 6 |
| Total Debt to Equity (Most Recent Quarter) | 6 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -19.30% |
| Return on Assets (Trailing Twelve Months) | -19.30% |
| Return on Assets (5 Year) | -21.12% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -23.11% |
| Return on Equity (Trailing Twelve Months) | -23.11% |
| Return on Equity (5 Year) | -26.20% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -21.93% |
| Return on Investment (Trailing Twelve Months) | -21.93% |
| Return on Investment (5 Year) | -24.67% |